Thus, PPAR agonists are prospective stand-alone or co-administered therapeutic drugs for many neurological or neurodegenerative diseases like amyotrophic lateral sclerosis, multiple sclerosis, cognitive impairment, and Alzheimer’s disease as well as mental disorders like depression, addiction, and schizophrenia. The gene discussed is PPARA; the disease is early-onset autosomal dominant Alzheimer disease.